Clinical trial
Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
NCT00304629 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00304629 |
|---|---|
| Title | Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease |
| Official title | Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | galantamine |
| Enrollment | 241 |
| Start date | Mar 1, 2000 |
| Completion | Mar 1, 2002 |
| First posted | Mar 20, 2006 |
| Last update posted | Feb 1, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: